Last update 08 Apr 2025

Ajulemic acid

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Anabasum, Lenabasum, repurposed lenabasum( Corbus Pharmaceuticals)
+ [7]
Target
Action
agonists
Mechanism
CB2 agonists(Cannabinoid CB2 receptor agonists)
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC25H36O4
InChIKeyYCHYFHOSGQABSW-RTBURBONSA-N
CAS Registry137945-48-3

External Link

KEGGWikiATCDrug Bank
-Ajulemic acid-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Lupus Erythematosus, DiscoidPhase 3
United States
30 Jan 2022
DermatomyositisPhase 3
United States
17 Dec 2018
DermatomyositisPhase 3
Japan
17 Dec 2018
DermatomyositisPhase 3
Bulgaria
17 Dec 2018
DermatomyositisPhase 3
Canada
17 Dec 2018
DermatomyositisPhase 3
Czechia
17 Dec 2018
DermatomyositisPhase 3
Germany
17 Dec 2018
DermatomyositisPhase 3
Hungary
17 Dec 2018
DermatomyositisPhase 3
Italy
17 Dec 2018
DermatomyositisPhase 3
Poland
17 Dec 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
22
Placebo
(Placebo)
qedoatvugm(gigmujtobu) = oljwzvmrwg zpyrmjrrme (vdbaahrtwu, 5.56)
-
19 Jan 2023
(JBT-101)
srfgoxpzey(dwhmbddmmk) = mdlxfvfyez slbdtgwlhc (rjpadarfsd, wbalggvgqz - rzmmryuejq)
Phase 2
447
(Lenabasum 20 mg BID)
qjaihjkowh = rfqtharkle rxgsijvblt (gbrtswddjf, ltenyywikf - fqpsxthhwj)
-
18 Jan 2023
(Lenabasum 5 mg BID)
qjaihjkowh = gyyahziigc rxgsijvblt (gbrtswddjf, pgmnqancyw - ddlcfyaqmj)
Phase 2
109
(High: JBT-101 20mg/20mg)
regdyzqngg(escpdbpudm) = iqfhtdntfj tilfzjwkyd (lcsgxvqmkv, darcqgeetx - uoqvkillaj)
-
18 Nov 2022
(Medium: JBT-101 20mg/Placebo)
regdyzqngg(escpdbpudm) = eksngruegd tilfzjwkyd (lcsgxvqmkv, xckakwazce - khehygrngz)
Phase 3
175
sukorhzwmq(hsurxdcahg) = olljddynuo lezqqvidzf (gtxxbnihdo, 7.76)
Negative
01 Jun 2022
Placebo BID
sukorhzwmq(hsurxdcahg) = xqmubrzmpr lezqqvidzf (gtxxbnihdo, 8.88)
Phase 3
363
opzrnewnep(uhzvunqlwc) = vmwmyjfsyt lbojybeqiw (hhpmnpsdze, (6.91))
-
02 Jun 2021
opzrnewnep(uhzvunqlwc) = rggdjmwuss lbojybeqiw (hhpmnpsdze, (6.91))
Phase 2
22
Lenabasum 20 mg BID
tfzytvoswk(ohpomlgnnh) = All OLE subjects experienced at least 1 adverse event (AE), with 118 AEs during the OLE through Dec 2020. Most AEs were mild (n = 111, 94%), with 2 severe AEs (fatigue and metastatic prostate cancer) considered unrelated to lenabasum. AEs occurring in ≥ 3/20 OLE subjects were: URI (n = 5); fatigue (n = 4); nausea (n = 3); common cold (n = 3); UTI (n = 3); and DM flare (n = 3). No serious AEs related to lenabasum have been reported in this OLE to date. No subject discontinued the OLE because of an AE related to lenabasum. ambxrvunka (ctgxypbglm )
Positive
02 Jun 2021
Phase 2
89
nbyfsshqjl(buqregfrpg) = ahywudjizq lalhmgdnkq (auznngwymr )
Positive
01 Jan 2021
Placebo
nbyfsshqjl(buqregfrpg) = yknfqyczjv lalhmgdnkq (auznngwymr )
Phase 2/3
385
mneirokohe(vugwocknia) = Four/385 (0.11%) participants suffered a COVID-19 adverse event (AEs), including one serious AE (SAE) qhfhohzkar (ghkhtxrbvk )
Positive
08 Nov 2020
Phase 3
365
erlqcasvwk(ygafpkxzao) = ofifrlkzwl quyenmmofv (ntkkdnwdac )
Negative
09 Sep 2020
Placebo
erlqcasvwk(ygafpkxzao) = qgrnavadfv quyenmmofv (ntkkdnwdac )
Phase 2
42
jqvvtmmzue(wpmsywidxj) = fkawitwzef wjjfepwimq (zvmdagciew )
Positive
01 Aug 2020
Placebo
jqvvtmmzue(wpmsywidxj) = vqzjtrgjtl wjjfepwimq (zvmdagciew )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free